Incyte is sticking to its strategy this year of finding “early-stage, exotic stuff”—paying Genesis Therapeutics $30 million upfront to use the biotech’s artificial intelligence platform to ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Under the financial terms of the deal, the Wilmington-based biotechnology company will make an upfront payment of $30 million to Genesis Therapeutics, which is eligible to receive up to $885 ...

About Genesis Therapeutics Genesis Therapeutics, Inc. is an AI-focused biotechnology company leveraging its generative and predictive AI platform, GEMS (Genesis Exploration of Molecular Space ...